Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024 Houston, Texas and Tuebingen, Germany, July 18, 2024 – Immatics N.V. (NASDAQ:...
Immatics Announces First Quarter 2024 Financial Results and Business Update Company Provides Clinical Data Update from Ongoing Phase 1...
Immatics Announces Full Year 2023 Financial Results and Corporate Update Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in...
Immatics Announces Pricing of $175 Million Public Offering Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ:...
Immatics Announces Proposed Public Offering Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX...
Immatics Announces Third Quarter 2023 Financial Results and Business Update ACTengine® IMA203 GEN1 TCR-T targeting PRAME showed 50% (6/12...
Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial...
Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy RMAT designation...
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics Collaboration combines...
Immatics veröffentlicht Ergebnisse des dritten Quartals 2022 sowie ein Update zur Geschäftsentwicklung Klinisches Daten-Update zu ACTengine®...
Immatics gibt garantiertes öffentliches Zeichnungsangebot von Stammaktien im Wert von $110 Millionen bekannt Houston, Texas und Tübingen...
Immatics Reports Interim Clinical Data Update on ACTengine® IMA203 TCR-T Monotherapy Targeting PRAME Company to host conference call today...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.